Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Quick Search
My eDoc
Session History
Support Wiki
Direct access to
document ID:

          Institute: MPI für medizinische Forschung     Collection: Abteilung Zellphysiologie     Display Documents

ID: 23203.0, MPI für medizinische Forschung / Abteilung Zellphysiologie
Selective antagonist for the cerebellar granule cell-specific g-aminobutyric acid type A receptor
Translation of Title:Selective antagonist for the cerebellar granule cell-specific g-aminobutyric acid type A receptor
Authors:Korpi, Esa R.; Kuner, Thomas; Seeburg, Peter H.; Lüddens, H.
Date of Publication (YYYY-MM-DD):1995-02
Title of Journal:Molecular Pharmacology
Journal Abbrev.:Mol. Pharmacol.
Issue / Number:2
Start Page:283
End Page:289
Review Status:Peer-review
Audience:Experts Only
Intended Educational Use:No
Abstract / Description:Numerous ligands affect inhibitory gamma-aminobutyric acid (GABA)A receptors, none of them showing strict receptor subtype specificity. We report here that a cerebellar GABAA receptor subtype can be uniquely modulated by furosemide but not by bumetanide, another Cl-/cation transport blocker. Furosemide specifically reversed the inhibition by GABA of t-[35S]butylbicyclophosphorothionate ([35S]TBPS) binding in the cerebellar granule cell layer, as detected by autoradiography of rat brain sections. With recombinant receptors expressed in Xenopus oocytes, furosemide antagonized potently (IC50, about 10 microM), rapidly, and reversibly GABA-evoked currents of cerebellar granule cell-specific alpha 6 beta 2 gamma 2 receptors but not alpha 1 beta 2 gamma 2 receptors (IC50, > 3 mM). Furosemide reversed GABA inhibition of [35S]TBPS binding and elevated basal [35S]TBPS binding only with alpha 6 beta 2 gamma 2 and alpha 6 beta 3 gamma 2 receptors and not with alpha 6 beta 1 gamma 2 or alpha 1 beta 1/2/3 gamma 2 receptors. It appeared to interact with the receptor complex via a novel recognition site that allosterically regulates the Cl- ionophore. Furosemide is the first subtype-selective GABAA receptor (alpha 6 beta 2/3 gamma 2) antagonist and should facilitate studies on cerebellar physiology. It might serve as a prototypic structure for the development of additional subtype-selective GABAA ligands.
External Publication Status:published
Document Type:Article
Communicated by:Wulf Kaiser
Affiliations:MPI für medizinische Forschung/Abteilung Zellphysiologie/
MPI für medizinische Forschung/Abteilung Molekulare Neurobiologie/
Identifiers:URI:http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?c... [Abstract]
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.